Neonatal SepsisNCT03880305
White Blood Cells and Platelets Indices as a Prognostic Factor in Neonatal Sepsis
An observational study of Neonatal Sepsis, run by Assiut University at 1 site in Egypt.
Trial summary
Sepsis is a complex condition initiated by a pathogen and mediated by cytokines followed by immune, inflammatory, and coagulation homeostasis disturbances, its evolution being dictated by a complicated balance between pro inflammatory and anti- inflammatory factors. Read more about this study
- Who is it for?
- Ages 1 day to 30 days
- Conditions the study is for
- Neonatal Sepsis
- What is being tested?
- complete blood count
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Apr 2019to 31 Mar 2020
- How long will I take part?
- 10 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 30 days
- All sexes
- No healthy volunteers
- Child
Study population: newborns with neonatal sepsis
Who may be able to join
- Neonates with suspected sepsis that show non-specific signs and symptoms or focal signs of infection, including temperature instability, hypotension, poor perfusion with pallor and mottled skin, metabolic acidosis, tachycardia or bradycardia, apnoea, respiratory distress, grunting, cyanosis, irritability, lethargy, seizures, feeding intolerance, abdominal distention, jaundice, petechiae, purpura, and bleeding. Later complications of sepsis might include respiratory failure, pulmonary hypertension, cardiac failure, shock, renal failure, liver dysfunction, cerebral edema or thrombosis, adrenal hemorrhage or insufficiency, bone marrow dysfunction (neutropenia, thrombocytopenia, anemia), and disseminated intravascular coagulation.
- Cases with neonatal sepsis diagnosed by isolating the causative agent from a normally sterile body site (blood, CSF, urine, pleural, joint, and peritoneal fluids (Andi L Shaneetal, 2017).
Who cannot join
- Obvious features of dehydration
- Major congenital malformations.
- GIT functional or organic obstruction, hematological disorders, hypersplenism, respiratory distress, malignancy and neurological emergency as intra cranial hemorrhage.
- Hypoxic ischemic encephalopathy.
- Post-surgical cases which need NICU observation.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Eslam Ahmad Roshdy
Asyut
Eslam A Roshdy, Physician, 00201066962696, iroshdy2@gmail.com
About this study
Sepsis is a complex condition initiated by a pathogen and mediated by cytokines followed by immune, inflammatory, and coagulation homeostasis disturbances, its evolution being dictated by a complicated balance between pro inflammatory and anti- inflammatory factors. Most of the short and long-term complications of the neonatal sepsis are strictly related to inflammatory mediators. Neonatal sepsis is associated with a mortality rate that ranges from 13 to 60% inspite of improved antibiotic therapy and an increased morbidity in survivors .
Read the detailed description
"Suspected sepsis" is one of the most frequently encountered diagnosis in neonatology because: a) a large number of newborns are evaluated for early or late sepsis based on risk factors and for fear of missing a correct diagnosis and a prompt treatment ; b) in neonates, the clinical signs of infection are not specific, late, and the differential diagnosis with neonatal respiratory distress syndrome, aspiration syndromes or neonatal maladaptation to extra-uterine life is difficult ; c) blood culture - the golden standard in neonatal sepsis diagnosis - provides late information, has a poor accuracy, and is not universally available; and d) up to date, there is no an ideal diagnostic tool for neonatal infection . Therefore, diagnosis of neonatal sepsis is still a challenge for neonatal medicine.
Antibiotic therapy is often initiated based upon clinical suspicion and/or the presence of risk factors, leading to excessive antibiotic therapy. Very often the diagnosis criteria for neonatal sepsis consists in documenting an infection in a newborn with severe systemic disease in which all possible noninfectious explanations for the patient's altered physiological status are either ruled out or unlikely.
The "gold standard", definitive test for neonatal sepsis is the isolation of the pathogen from blood. However, its accuracy is influenced by multiple factors a) contamination during sampling; b) sampling after antibiotic therapy was started; c) insufficient sampling volume; d) low colony count bacteremia. Accuracy of the blood culture varies between8 and 73% in various studies .
Despite hundreds of published studies, there is still no consensus regarding the best screening test or panel of tests for rapid detection of neonatal sepsis. Recently, new acute phase proteins, cytokines, cell surface antigens, and bacterial genome are used to improve the neonatal sepsis diagnosis but data are still under evaluation and most of these tests are either not clinically available or they are expensive .
Accumulating evidence indicates that the CBC is an effective predictor of prognosis and mortality in many disease states, including hematological disease, neoplasms, and severe infections. Therefore, non- specific changes in the CBC in critically ill neonates could be considered a key prognostic factor in the evaluation of survival prediction in these patients .
Some prognostic scoring systems with performance status, clinical symptoms and biochemical parameters help to guide accurate prediction of the prognosis, such as the acute physiology and chronic health evaluation, yet are considered too complex for general clinical use. Therefore, the prediction of clinical events with laboratory parameters, including complete blood cell count (CBC), has become an increased focus of research .
Total leukocyte count (TLC), total neutrophil count, ANC, immature neutrophil count, immature/total neutrophil ratio (I:T ratio), immature/mature neutrophil ratio (I:M ratio), neutrophil degenerative changes (vacuolization, toxic granulations, and Döhle bodies), and platelet count are the most used hematological parameters for Early Onset Sepsis evaluation . Most of the hematological screening panels for Early Onset Sepsis use a total leukocyte count < 5000 cells/mm3 or > 20.000 cells/mm3, an I:T ratio > 0.2, and total outside the normal range. TLC increases in severe neonatal infections (both mature and immature cells) possible secondary to growth factors and cytokine release that stimulate the bone marrow production.
Thrombocytopenia is one of the early but non-specific indicator of neonatal sepsis with or without DIC. It can be caused by bacterial, viral, fungal and parasitic infections and other non-infectious causes. The overall prevalence of thrombocytopenia in neonatal age group varies from1- 5%, and is reported to be much higher in newborns admitted to intensive care units, i.e. ranging from 22% to 35%. Severe thrombocytopenia (50000/mm3) was found to be present in 2.4% patients admitted in NICU.Bleeding is a major complication of thrombocytopenia but is generally limited to infants with count< 30000/mm3. Studies have shown that approximately 50% cases of culture proven of sepsis get thrombocytopenia .Changes in other platelet indices, like MPV(mean platelet volume) and PDW (platelet distribution width) have also been examined in relationship to neonatal sepsis in some studies .
Platelet indices (platelet counts, platelet distribution width-(PDW), mean platelet volume (MPV)) are one such set of parameters which can be helpful for the diagnosis and hence early treatment of neonatal sepsis. Advantages of platelet indices are that the sample for these can be drawn at the same time as that for other investigations and require no special sampling techniques and are easily available. Some studies had reported a low platelet counts, high mean platelet volume and platelet distribution width was observed in sepsis cases with a statistically significant difference as compared to controls .
- Conditions
- Neonatal Sepsis
- Being tested
- complete blood count
- Keywords
- neonatal sepsis, white blood cells, platelets
- Medical subject headings
- Neonatal Sepsis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
complete blood countDiagnostic test
Also called blood culture
complete blood count
What is being measured
The primary outcome is the main question the study is designed to answer.
white blood cells
total leucocytic count
Measured: one year
white blood cells indices
total neutrophil count
Measured: one year
Platelets indices
Platelet count
Measured: one year
Platelets indices
Platelet distribution width(PDW)
Measured: one year
Platelets indices
Mean platelet volume
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2019
- Study start1 Apr 2019 (estimated)
- Primary completion30 Sep 2019 (estimated)
- Study completion31 Mar 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neonatal SepsisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
- Target duration
- 10 Days
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Eslam Ahmad Roshdy, Assiut University
- Investigators
- Eslam A Roshdy, Principal investigator, Assiut University Faculty of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03880305
- Sponsor's protocol ID
- WBCPLATNS
- Status last verified
- Mar 2019
- First submitted
- 13 Mar 2019
- Last updated
- 19 Mar 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: all collected IPD
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- White Blood Cells and Platelets Indices as a Prognostic Factor in Neonatal Sepsis
- ClinicalTrials.gov ID
- NCT03880305
- Acronym / sponsor ID
- WBCPLATNS
- Conditions
- Neonatal Sepsis
- Keywords
- neonatal sepsis, white blood cells, platelets
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Apr 2019 (estimated)
- Primary completion
- 30 Sep 2019 (estimated)
- Study completion
- 31 Mar 2020 (estimated)
- First posted
- 19 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sepsis is a complex condition initiated by a pathogen and mediated by cytokines followed by immune, inflammatory, and coagulation homeostasis disturbances, its evolution being dictated by a complicated balance between pro inflammatory and anti- inflammatory factors. Most of the short and long-term complications of the neonatal sepsis are strictly related to inflammatory mediators. Neonatal sepsis is associated with a mortality rate that ranges from 13 to 60% inspite of improved antibiotic therapy and an increased morbidity in survivors .
Detailed description
"Suspected sepsis" is one of the most frequently encountered diagnosis in neonatology because: a) a large number of newborns are evaluated for early or late sepsis based on risk factors and for fear of missing a correct diagnosis and a prompt treatment ; b) in neonates, the clinical signs of infection are not specific, late, and the differential diagnosis with neonatal respiratory distress syndrome, aspiration syndromes or neonatal maladaptation to extra-uterine life is difficult ; c) blood culture - the golden standard in neonatal sepsis diagnosis - provides late information, has a poor accuracy, and is not universally available; and d) up to date, there is no an ideal diagnostic tool for neonatal infection . Therefore, diagnosis of neonatal sepsis is still a challenge for neonatal medicine.
Antibiotic therapy is often initiated based upon clinical suspicion and/or the presence of risk factors, leading to excessive antibiotic therapy. Very often the diagnosis criteria for neonatal sepsis consists in documenting an infection in a newborn with severe systemic disease in which all possible noninfectious explanations for the patient's altered physiological status are either ruled out or unlikely.
The "gold standard", definitive test for neonatal sepsis is the isolation of the pathogen from blood. However, its accuracy is influenced by multiple factors a) contamination during sampling; b) sampling after antibiotic therapy was started; c) insufficient sampling volume; d) low colony count bacteremia. Accuracy of the blood culture varies between8 and 73% in various studies .
Despite hundreds of published studies, there is still no consensus regarding the best screening test or panel of tests for rapid detection of neonatal sepsis. Recently, new acute phase proteins, cytokines, cell surface antigens, and bacterial genome are used to improve the neonatal sepsis diagnosis but data are still under evaluation and most of these tests are either not clinically available or they are expensive .
Accumulating evidence indicates that the CBC is an effective predictor of prognosis and mortality in many disease states, including hematological disease, neoplasms, and severe infections. Therefore, non- specific changes in the CBC in critically ill neonates could be considered a key prognostic factor in the evaluation of survival prediction in these patients .
Some prognostic scoring systems with performance status, clinical symptoms and biochemical parameters help to guide accurate prediction of the prognosis, such as the acute physiology and chronic health evaluation, yet are considered too complex for general clinical use. Therefore, the prediction of clinical events with laboratory parameters, including complete blood cell count (CBC), has become an increased focus of research .
Total leukocyte count (TLC), total neutrophil count, ANC, immature neutrophil count, immature/total neutrophil ratio (I:T ratio), immature/mature neutrophil ratio (I:M ratio), neutrophil degenerative changes (vacuolization, toxic granulations, and Döhle bodies), and platelet count are the most used hematological parameters for Early Onset Sepsis evaluation . Most of the hematological screening panels for Early Onset Sepsis use a total leukocyte count < 5000 cells/mm3 or > 20.000 cells/mm3, an I:T ratio > 0.2, and total outside the normal range. TLC increases in severe neonatal infections (both mature and immature cells) possible secondary to growth factors and cytokine release that stimulate the bone marrow production.
Thrombocytopenia is one of the early but non-specific indicator of neonatal sepsis with or without DIC. It can be caused by bacterial, viral, fungal and parasitic infections and other non-infectious causes. The overall prevalence of thrombocytopenia in neonatal age group varies from1- 5%, and is reported to be much higher in newborns admitted to intensive care units, i.e. ranging from 22% to 35%. Severe thrombocytopenia (50000/mm3) was found to be present in 2.4% patients admitted in NICU.Bleeding is a major complication of thrombocytopenia but is generally limited to infants with count< 30000/mm3. Studies have shown that approximately 50% cases of culture proven of sepsis get thrombocytopenia .Changes in other platelet indices, like MPV(mean platelet volume) and PDW (platelet distribution width) have also been examined in relationship to neonatal sepsis in some studies .
Platelet indices (platelet counts, platelet distribution width-(PDW), mean platelet volume (MPV)) are one such set of parameters which can be helpful for the diagnosis and hence early treatment of neonatal sepsis. Advantages of platelet indices are that the sample for these can be drawn at the same time as that for other investigations and require no special sampling techniques and are easily available. Some studies had reported a low platelet counts, high mean platelet volume and platelet distribution width was observed in sepsis cases with a statistically significant difference as compared to controls .
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Target follow-up
- 10 Days
Who may qualify
- Ages
- 1 day to 30 days
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- newborns with neonatal sepsis
Key inclusion criteria (2 listed)
- Neonates with suspected sepsis that show non-specific signs and symptoms or focal signs of infection, including temperature instability, hypotension, poor perfusion with pallor and mottled skin, metabolic acidosis, tachycardia or bradycardia, apnoea, respiratory distress, grunting, cyanosis, irritability, lethargy, seizures, feeding intolerance, abdominal distention, jaundice, petechiae, purpura, and bleeding. Later complications of sepsis might include respiratory failure, pulmonary hypertension, cardiac failure, shock, renal failure, liver dysfunction, cerebral edema or thrombosis, adrenal hemorrhage or insufficiency, bone marrow dysfunction (neutropenia, thrombocytopenia, anemia), and disseminated intravascular coagulation.
- Cases with neonatal sepsis diagnosed by isolating the causative agent from a normally sterile body site (blood, CSF, urine, pleural, joint, and peritoneal fluids (Andi L Shaneetal, 2017).
Key exclusion criteria (5 listed)
- Obvious features of dehydration
- Major congenital malformations.
- GIT functional or organic obstruction, hematological disorders, hypersplenism, respiratory distress, malignancy and neurological emergency as intra cranial hemorrhage.
- Hypoxic ischemic encephalopathy.
- Post-surgical cases which need NICU observation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| complete blood countAlso: blood culturecomplete blood count | Diagnostic test | – |
Primary outcome
white blood cells
Time frame: one year
total leucocytic count
white blood cells indices
Time frame: one year
total neutrophil count
Platelets indices
Time frame: one year
Platelet count
Platelets indices
Time frame: one year
Platelet distribution width(PDW)
Platelets indices
Time frame: one year
Mean platelet volume
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2019.
- Individual participant dataSharing planned: Undecided. all collected IPD
Related trials for Neonatal Sepsis
RecruitingPhase 1
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)
Chronic Granulomatous Disease, Infection
RecruitingPhase 3
Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates
Sepsis, PROM, Preterm (Pregnancy)
Not yet recruitingEarly Phase 1
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
EBV Viremia, CMV Viremia
Not yet recruiting
G-CSF In Neonatal Sepsis With Neutropenia
Neonatal Sepsis, Neutropenia
RecruitingObservational study
Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections
Neonatal Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eslam A Roshdy principal investigator
Assiut University Faculty of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neonatal Sepsis, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Eslam A Roshdy (00201066962696, iroshdy92@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
white blood cells (time frame: one year). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2019.